ES2989651T3 - Uso de una composición vitamínica para preparar un fármaco para prevenir, tratar o retrasar la enfermedad de Alzheimer - Google Patents
Uso de una composición vitamínica para preparar un fármaco para prevenir, tratar o retrasar la enfermedad de Alzheimer Download PDFInfo
- Publication number
- ES2989651T3 ES2989651T3 ES18763903T ES18763903T ES2989651T3 ES 2989651 T3 ES2989651 T3 ES 2989651T3 ES 18763903 T ES18763903 T ES 18763903T ES 18763903 T ES18763903 T ES 18763903T ES 2989651 T3 ES2989651 T3 ES 2989651T3
- Authority
- ES
- Spain
- Prior art keywords
- vitamin
- parts
- composition
- disease
- refers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 65
- 229940088594 vitamin Drugs 0.000 title claims abstract description 47
- 229930003231 vitamin Natural products 0.000 title claims abstract description 47
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 47
- 239000011782 vitamin Substances 0.000 title claims abstract description 47
- 150000003722 vitamin derivatives Chemical class 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title abstract description 33
- 239000003814 drug Substances 0.000 title abstract description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 48
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 24
- 239000011718 vitamin C Substances 0.000 claims abstract description 24
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 23
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 36
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 36
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 27
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 22
- 229960003495 thiamine Drugs 0.000 claims description 22
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 21
- 229960002477 riboflavin Drugs 0.000 claims description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- 235000019158 vitamin B6 Nutrition 0.000 claims description 20
- 239000011726 vitamin B6 Substances 0.000 claims description 20
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 19
- 235000010374 vitamin B1 Nutrition 0.000 claims description 19
- 239000011691 vitamin B1 Substances 0.000 claims description 19
- 229940011671 vitamin b6 Drugs 0.000 claims description 18
- 229960003512 nicotinic acid Drugs 0.000 claims description 17
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 17
- 235000019164 vitamin B2 Nutrition 0.000 claims description 17
- 239000011716 vitamin B2 Substances 0.000 claims description 17
- 229930003451 Vitamin B1 Natural products 0.000 claims description 16
- 235000019163 vitamin B12 Nutrition 0.000 claims description 16
- 239000011715 vitamin B12 Substances 0.000 claims description 16
- 229930003471 Vitamin B2 Natural products 0.000 claims description 15
- 235000019160 vitamin B3 Nutrition 0.000 claims description 14
- 239000011708 vitamin B3 Substances 0.000 claims description 14
- 229930003779 Vitamin B12 Natural products 0.000 claims description 13
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 13
- 235000019152 folic acid Nutrition 0.000 claims description 13
- 239000011724 folic acid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 13
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 12
- 235000009492 vitamin B5 Nutrition 0.000 claims description 12
- 239000011675 vitamin B5 Substances 0.000 claims description 12
- 235000019159 vitamin B9 Nutrition 0.000 claims description 12
- 239000011727 vitamin B9 Substances 0.000 claims description 12
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 11
- 229930003537 Vitamin B3 Natural products 0.000 claims description 11
- 229960000304 folic acid Drugs 0.000 claims description 11
- 229930003571 Vitamin B5 Natural products 0.000 claims description 10
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 10
- 229960002079 calcium pantothenate Drugs 0.000 claims description 10
- 229930003761 Vitamin B9 Natural products 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 229960004874 choline bitartrate Drugs 0.000 claims description 8
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 8
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 6
- 235000019192 riboflavin Nutrition 0.000 claims description 6
- 239000002151 riboflavin Substances 0.000 claims description 6
- 235000019157 thiamine Nutrition 0.000 claims description 6
- 239000011721 thiamine Substances 0.000 claims description 6
- 235000011912 vitamin B7 Nutrition 0.000 claims description 6
- 239000011735 vitamin B7 Substances 0.000 claims description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 229930003756 Vitamin B7 Natural products 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000000639 cyanocobalamin Nutrition 0.000 claims 1
- 239000011666 cyanocobalamin Substances 0.000 claims 1
- 229960002104 cyanocobalamin Drugs 0.000 claims 1
- 235000008160 pyridoxine Nutrition 0.000 claims 1
- 239000011677 pyridoxine Substances 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 abstract description 22
- 239000011720 vitamin B Substances 0.000 abstract description 22
- 229930003270 Vitamin B Natural products 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 description 38
- 230000037149 energy metabolism Effects 0.000 description 29
- 241000700159 Rattus Species 0.000 description 28
- 210000004556 brain Anatomy 0.000 description 25
- 108090000790 Enzymes Proteins 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 230000004060 metabolic process Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000013016 learning Effects 0.000 description 13
- 230000002438 mitochondrial effect Effects 0.000 description 12
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 12
- 230000007087 memory ability Effects 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 10
- 210000003710 cerebral cortex Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000010877 cognitive disease Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 8
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 8
- 230000004153 glucose metabolism Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 6
- 238000012347 Morris Water Maze Methods 0.000 description 6
- 210000005013 brain tissue Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000003920 cognitive function Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 6
- 229960000367 inositol Drugs 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- -1 B12 Chemical compound 0.000 description 5
- 229960004050 aminobenzoic acid Drugs 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229960003135 donepezil hydrochloride Drugs 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 4
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000006886 spatial memory Effects 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 235000021467 vitamin B7(Biotin) Nutrition 0.000 description 4
- 101000903027 Homo sapiens ATP synthase subunit beta, mitochondrial Proteins 0.000 description 3
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000009227 behaviour therapy Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 208000027061 mild cognitive impairment Diseases 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- 102100022890 ATP synthase subunit beta, mitochondrial Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000006677 mitochondrial metabolism Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- 208000026680 Metabolic Brain disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- KYOBSHFOBAOFBF-UHFFFAOYSA-N UMP Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-UHFFFAOYSA-N 0.000 description 1
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 201000002670 dry beriberi Diseases 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 230000006571 energy metabolism pathway Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940042040 innovative drug Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000031339 positive regulation of inflammatory response Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011822 triple transgenic animal model Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710131111.XA CN108567792A (zh) | 2017-03-07 | 2017-03-07 | 一种治疗阿尔茨海默病的复合维生素组合物 |
| PCT/CN2018/077107 WO2018161808A1 (zh) | 2017-03-07 | 2018-02-24 | 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2989651T3 true ES2989651T3 (es) | 2024-11-27 |
Family
ID=63448062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18763903T Active ES2989651T3 (es) | 2017-03-07 | 2018-02-24 | Uso de una composición vitamínica para preparar un fármaco para prevenir, tratar o retrasar la enfermedad de Alzheimer |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11464797B2 (OSRAM) |
| EP (2) | EP4461361A3 (OSRAM) |
| JP (3) | JP7169285B2 (OSRAM) |
| CN (2) | CN108567792A (OSRAM) |
| AU (2) | AU2018229920B2 (OSRAM) |
| BR (1) | BR112019018652A2 (OSRAM) |
| CA (1) | CA3054972A1 (OSRAM) |
| ES (1) | ES2989651T3 (OSRAM) |
| WO (1) | WO2018161808A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021023069A1 (zh) * | 2019-08-02 | 2021-02-11 | 上海日馨生物科技有限公司 | Tpk作为靶点在阿尔茨海默病的应用 |
| KR102275981B1 (ko) * | 2020-03-31 | 2021-07-13 | 고려은단주식회사 | 섬쑥부쟁이 추출물과 비타민 b 복합체의 혼합물을 포함하는 인지기능 개선용 조성물 |
| WO2023248374A1 (ja) * | 2022-06-22 | 2023-12-28 | 源一郎 杣 | 糖尿病性認知症に対する予防薬及び治療薬 |
| CN119055674B (zh) * | 2024-11-06 | 2025-02-18 | 中国医学科学院北京协和医院 | 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626884A (en) | 1995-08-18 | 1997-05-06 | Lockett; Curtis G. | Treatment of sickle cell disease |
| WO1999064022A1 (en) | 1998-06-10 | 1999-12-16 | Crum Albert B | Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| AU2003218319A1 (en) | 2002-03-22 | 2003-10-13 | Doc's Guide, Inc. | Multivitamin and mineral nutritional supplement |
| CA2583972A1 (en) | 2004-10-14 | 2006-10-19 | Adventures Plus Pty Ltd | A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals |
| US20110275591A1 (en) * | 2004-12-01 | 2011-11-10 | Concourse Health Sciences Llc | Cocktail for modulation of alzheimer's disease |
| US20060148727A1 (en) * | 2004-12-01 | 2006-07-06 | Curt Hendrix | Folate based composition for neurological and cognitive applications |
| WO2009002166A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
| US9763989B2 (en) * | 2007-08-03 | 2017-09-19 | Shaklee Corporation | Nutritional supplement system |
| JP4206428B1 (ja) * | 2008-06-09 | 2009-01-14 | 正樹 今川 | 認知症を処置するための組成物及びその利用 |
| KR20110004691A (ko) * | 2009-07-08 | 2011-01-14 | 대한민국(농촌진흥청장) | 뇌기능 개선효과를 가지는 붉나무 추출물을 포함하는 약학조성물 및 건강식품조성물 |
| WO2011121150A1 (es) * | 2010-03-31 | 2011-10-06 | Vegenat, S.A. | Producto alimenticio enteral u oral especialmente destinado para la nutrición, prevención y mejora de alteraciones neurológicas, neurodegenerativas o trastornos cognitivos |
| EP2568826A4 (en) * | 2010-05-13 | 2014-03-26 | Nitromega Corp | NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE |
| CN108420827A (zh) | 2010-07-22 | 2018-08-21 | 雷文制药有限公司 | 包含磁偶极子稳定化溶液的组合物及其用途 |
| KR20130015932A (ko) * | 2011-08-05 | 2013-02-14 | 연세대학교 산학협력단 | 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물 |
| WO2013066151A1 (en) | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Improving recognition |
| US20150044138A1 (en) * | 2012-03-02 | 2015-02-12 | N.V. Nutricia | Method for improving functional synaptic connectivity |
| WO2014025905A1 (en) * | 2012-08-07 | 2014-02-13 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| WO2014026161A1 (en) * | 2012-08-10 | 2014-02-13 | Aquavit Pharmaceuticals, Inc. | Vitamin supplement compositions for injection |
| CN104337813A (zh) | 2013-07-23 | 2015-02-11 | 上海泽生科技开发有限公司 | 使用维生素b组合物促进胃肠系统动力的方法 |
| CN104256652A (zh) | 2014-10-08 | 2015-01-07 | 李明刚 | 一种口服复合维生素纳米脂质体 |
| CN104922164B (zh) | 2014-12-12 | 2020-06-02 | 中国医科大学 | 一种治疗阿尔茨海默病的药物复合制剂 |
| CN106265696A (zh) * | 2015-06-12 | 2017-01-04 | 上海泽生科技开发有限公司 | 使用复合维生素b、c组合物促进胃肠系统动力的方法 |
| CN104856048A (zh) | 2015-06-18 | 2015-08-26 | 安徽医联大成医药科技有限公司 | 一种促进肠胃蠕动的食品配方及其制备方法 |
| CN108079008A (zh) * | 2016-11-23 | 2018-05-29 | 上海泽生科技开发股份有限公司 | 促进胃肠系统动力的复合维生素组合物 |
-
2017
- 2017-03-07 CN CN201710131111.XA patent/CN108567792A/zh active Pending
-
2018
- 2018-02-24 CN CN201880015481.XA patent/CN110520135A/zh active Pending
- 2018-02-24 ES ES18763903T patent/ES2989651T3/es active Active
- 2018-02-24 CA CA3054972A patent/CA3054972A1/en not_active Abandoned
- 2018-02-24 BR BR112019018652A patent/BR112019018652A2/pt not_active Application Discontinuation
- 2018-02-24 WO PCT/CN2018/077107 patent/WO2018161808A1/zh not_active Ceased
- 2018-02-24 JP JP2019548652A patent/JP7169285B2/ja active Active
- 2018-02-24 US US16/491,560 patent/US11464797B2/en active Active
- 2018-02-24 EP EP24189913.7A patent/EP4461361A3/en not_active Withdrawn
- 2018-02-24 EP EP18763903.4A patent/EP3593805B1/en active Active
- 2018-02-24 AU AU2018229920A patent/AU2018229920B2/en active Active
-
2022
- 2022-09-15 US US17/945,684 patent/US20230248756A1/en not_active Abandoned
- 2022-10-28 JP JP2022172956A patent/JP2023011769A/ja active Pending
-
2024
- 2024-04-24 AU AU2024202678A patent/AU2024202678A1/en active Pending
- 2024-11-14 JP JP2024198677A patent/JP2025024089A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108567792A (zh) | 2018-09-25 |
| JP7169285B2 (ja) | 2022-11-10 |
| US20230248756A1 (en) | 2023-08-10 |
| CN110520135A (zh) | 2019-11-29 |
| JP2023011769A (ja) | 2023-01-24 |
| EP3593805B1 (en) | 2024-07-24 |
| EP4461361A3 (en) | 2025-01-01 |
| AU2018229920A1 (en) | 2019-10-03 |
| WO2018161808A1 (zh) | 2018-09-13 |
| JP2020509072A (ja) | 2020-03-26 |
| US20200030358A1 (en) | 2020-01-30 |
| EP3593805A1 (en) | 2020-01-15 |
| AU2018229920B2 (en) | 2024-02-08 |
| BR112019018652A2 (pt) | 2020-04-07 |
| AU2024202678A1 (en) | 2024-05-16 |
| JP2025024089A (ja) | 2025-02-19 |
| CA3054972A1 (en) | 2018-09-13 |
| US11464797B2 (en) | 2022-10-11 |
| EP3593805A4 (en) | 2020-10-07 |
| EP4461361A2 (en) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230248756A1 (en) | Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease | |
| Geisler et al. | DNP, mitochondrial uncoupling, and neuroprotection: A little dab'll do ya | |
| ES2822178T3 (es) | Formulaciones dietéticas que promueven la regeneración de tejidos/órganos | |
| ES3026784T3 (en) | Non-therapeutic use of urolithin a for improving cognitive function. | |
| ES2542412T3 (es) | Composición útil para el tratamiento de trastornos del metabolismo de los lípidos | |
| Liu et al. | Depression-like behaviors in mice subjected to co-treatment of high-fat diet and corticosterone are ameliorated by AICAR and exercise | |
| Braga Neto et al. | Current concepts in the treatment of hereditary ataxias | |
| McGeown et al. | Nutritional interventions to improve neurophysiological impairments following traumatic brain injury: a systematic review | |
| CN116528865A (zh) | 用于细胞能量的使用橄榄苦苷和烟酰胺核糖核苷的组合的组合物和方法 | |
| Turkel et al. | Mitochondrial transplantation as a possible therapeutic option for sarcopenia | |
| CN1985993B (zh) | 增强记忆力的复方制剂 | |
| ES2613977T3 (es) | Composiciones farmacéuticas con dosis elevadas de biotina | |
| Majolo et al. | Recent Drugs Tested in Clinical Trials for Alzheimer´ s and Parkinson´ s Diseases Treatment: Current Approaches in Tracking New Drugs | |
| Wei et al. | Current situation and challenge of exogenous 3-hydroxybutyrate derived from polyhydroxyalkanoates for elderly health: A review | |
| WO2011041920A2 (es) | Composición nutracéutica que comprende extracto de shilajit, ácido fólico, vitamina b12 y vitamina b6 y su uso para prevenir y/o tratar enfermedades neurodegenerativas y/o el deterioro cognitivo asociado al envejecimiento cerebral | |
| Shahouzehi et al. | Concomitant Administration of L-carnitine and Performing HighIntensity Interval Training Effects on the Genes Involved in Mitochondrial Fusion and Apoptosis in Rat Liver. | |
| CN103393702A (zh) | 一种增强急进高原人群记忆力的药物组合物及其制备方法 | |
| CN111467385B (zh) | 组合物在预防或治疗神经退行性疾病中的用途 | |
| Hoang et al. | Restoration of cellular energetic balance with L-carnitine in the neuro-bioenergetic approach for cancer prevention and treatment | |
| Elifani et al. | I17 Curcumin-supplemented diet preserves body weight and ameliorates intestinal functionality in R6/2 mice | |
| EP4082537A1 (en) | Anti-obesity composition containing colchicine and metformin as effective agents | |
| Agrawal et al. | Evaluation of Hordenine’s Therapeutic Potential in Alzheimer’s Disease-induced Cognitive and Oxidative Impairments | |
| Keleş et al. | Histopathological and Biochemical Investigation of Silymarin’s Inhibitory Effect on the Formation of Obesity Induced by High Fat Diet in Rats | |
| Davis et al. | metabolite is an inactive 2-N-glucuronide conjugate. It is rap-idly absorbed in its entirety with few first-pass metabolism | |
| Bhong | Understanding the Role of Intestinal Microbiota and Vitamins in Parkinson’s Disease |